<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610189</url>
  </required_header>
  <id_info>
    <org_study_id>CVL-751-1006</org_study_id>
    <nct_id>NCT05610189</nct_id>
  </id_info>
  <brief_title>Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease</brief_title>
  <official_title>A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease to Evaluate the Clinical Bioequivalence Between Tavapadon Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerevel Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerevel Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the bioequivalence (BE) of tavapadon 15&#xD;
      milligram (mg) tablet to 3x5 mg tablets in participants with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2022</start_date>
  <completion_date type="Anticipated">November 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUCÏ„) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum Steady-state Plasma Concentration (Cmin,ss) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Steady-state Plasma Concentration (Cavg,ss) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentration (Ctrough) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Observed Concentration (Tmax) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of Fluctuation [(Cmax - Cmin)/Cavg,ss] of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak-to-Trough Ratio (PTR) of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swing [(Cmax - Cmin)/Cmin,ss] of Tavapadon</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance of Tavapadon From Plasma (CL/F)</measure>
    <time_frame>Pre-dose and at multiple timepoints post-dose up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and AEs by Severity</measure>
    <time_frame>Up to Day 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Values</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Vital Sign Values</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Significant Changes in Physical and Neurological Examination Results</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Suicidality Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to Day 29</time_frame>
    <description>The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, if present (from 1 to 5, with 5 being the most severe). Greater lethality or potential lethality of suicidal behaviors (endorsed on the behavior subscale) indicates increased risk.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tavapadon 1x15 mg tablet, orally, once daily (QD) from Day 15 to 21.&#xD;
Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 22 to 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive tavapadon 3x5 mg tablets, orally, QD from Day 15 to 21.&#xD;
Participants will receive tavapadon 1x15 mg tablet, orally, QD from Day 22 to 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tavapadon</intervention_name>
    <description>Oral tablets</description>
    <arm_group_label>Cohort 1: Tavapadon 1x15 mg Followed by 3x5 mg</arm_group_label>
    <arm_group_label>Cohort 2: Tavapadon 3x5 mg Followed by 1x15 mg</arm_group_label>
    <other_name>CVL-751</other_name>
    <other_name>PF-06649751</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Body mass index of 17.5 to 38.0 kilograms per square meter (kg/m^2), inclusive, and&#xD;
             total body weight &gt;50 kg (110 pounds [lb]) at Screening.&#xD;
&#xD;
          2. Participants with a diagnosis of Parkinson's disease (PD) that is consistent with the&#xD;
             United Kingdom (UK) Parkinson's Disease Society Brain Bank diagnostic criteria.&#xD;
&#xD;
          3. Must be modified Hoehn &amp; Yahr Stage I-III inclusive.&#xD;
&#xD;
          4. Must be on a stable dose of L-Dopa of at least 300 mg daily in conjunction with a&#xD;
             dopa-decarboxylase inhibitor (e.g., L-Dopa/carbidopa, L Dopa/carbidopa/entacapone or&#xD;
             L-Dopa/benserazide) administered at least 3 times per day for at least 2 weeks prior&#xD;
             to the Day 1 Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants with a history or clinical features consistent with essential tremor,&#xD;
             atypical or secondary parkinsonian syndrome (including, but not limited to,&#xD;
             progressive supranuclear palsy, multiple system atrophy, cortico-basal degeneration,&#xD;
             or drug-induced or poststroke parkinsonism).&#xD;
&#xD;
          2. Participants with a history of psychosis or hallucinations within the previous 12&#xD;
             months.&#xD;
&#xD;
          3. Participants with epilepsy, or history of epilepsy, or conditions that lower seizure&#xD;
             threshold, seizures of any etiology (including substance or drug withdrawal), or who&#xD;
             have increased risk of seizures as evidenced by history of electroencephalogram with&#xD;
             epileptiform activity are excluded. Participants with a history of febrile seizures&#xD;
             only are allowed with medical monitor approval.&#xD;
&#xD;
          4. History of substance or alcohol-use disorder (excluding nicotine; Diagnostic and&#xD;
             Statistical Manual of Mental Disorders, 5th edition criteria) within 2 years prior to&#xD;
             signing the informed consent form (ICF).&#xD;
&#xD;
          5. Participants who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 4 (Active Suicidal&#xD;
             Ideation with Some Intent to Act, Without Specific Plan) and whose most recent episode&#xD;
             meeting criteria for this C-SSRS Item 4 occurred within the last 6 months, OR&#xD;
             Participants who answer &quot;Yes&quot; on the C-SSRS Suicidal Ideation Item 5 (Active Suicidal&#xD;
             Ideation with Specific Plan and Intent) and whose most recent episode meeting criteria&#xD;
             for this C-SSRS Item 5 occurred within the last 6 months OR Participants who answer&#xD;
             &quot;Yes&quot; on any of the 5 C-SSRS Suicidal Behavior Items (actual attempt, interrupted&#xD;
             attempt, aborted attempt, preparatory acts, or behavior) and whose most recent episode&#xD;
             meeting criteria for any of these 5 C-SSRS Suicidal Behavior Items occurred within the&#xD;
             last 2 years, OR Participants who, in the opinion of the investigator, present a&#xD;
             serious risk of suicide.&#xD;
&#xD;
          6. Participants who have attempted suicide in the past.&#xD;
&#xD;
          7. Positive result for human immunodeficiency virus (HIV) antibody, hepatitis B surface&#xD;
             antigen, hepatitis B core antibody, or hepatitis C antibody with detectable viral&#xD;
             ribonucleic acid (RNA) levels at Screening.&#xD;
&#xD;
          8. Have been diagnosed with symptomatic coronavirus disease (COVID-19) or test positive&#xD;
             (i.e., using polymerase chain reaction [PCR] or rapid antigen test) for COVID-19&#xD;
             within 30 days prior to signing the ICF.&#xD;
&#xD;
          9. Participants taking strong or moderate cytochrome P450 family 3 subfamily A member 4&#xD;
             (CYP3A4) inducers or inhibitors or who would be likely to require concomitant therapy&#xD;
             with CYP3A4 inducers or inhibitors during the trial.&#xD;
&#xD;
        NOTE: Other protocol-defined inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amanda McGill</last_name>
    <phone>(919) 456-6288</phone>
    <email>Amanda.McGill@ppd.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Alamitos, California</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando, Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Miami, Florida</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Decatur, Georgia</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Farmington Hills, Michigan</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 2, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>April 24, 2023</last_update_submitted>
  <last_update_submitted_qc>April 24, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

